Shenzhen, China - On November 15, the 24^th China International High-tech Fair (“CHTF”) kicked off in Shenzhen. Shanghai MicroPort MedBot (Group) Co., Ltd. (“MicroPort^® MedBot^®”) presented its self-developed DFVision^® 3D Electronic Laparoscopic and Honghu¹ Orthopedic Surgical Robot at the fair. In addition to demonstration of its cutting-edge technology and innovation achievements in the field of high-end medicine, MicroPort^® MedBot^® also promoted knowledge related to robotic surgery to the audience. Prof. Shijian Yi, Vice President and Prof. Feng Wang, Director of the Department of Urology of The South China Hospital affiliated to Shenzhen University, delivered a speech respectively on “Thyroid Surgery Performed by the Chinese-developed Surgical Robot” and “The Substitution Journey of Surgical Robots” during the conference. Through the online and offline linkage, CHTF, a national arena for innovative products and cutting-edge technologies, has brought a "technology feast" of experience and exchange to tens of thousands of audiences.

Known as “the leading exhibition of science and technology in China”, CHTF is an important window for opening up in the field of high-end and innovative technologies, and also a key platform for Industrialization of high-tech achievements, jointly held by Ministry of Commerce, Ministry of Science and Technology, Ministry of Industry and Information Technology, National Development and Reform Commission, Ministry of Agriculture and Rural Affairs, State Intellectual Property Office, Chinese Academy of Sciences, Chinese Academy of Engineering and People's Government of Shenzhen Municipality. Since its inception in 1999, 23 sessions have been successfully held. After years of development, CHTF has grown into an important window for opening up China's high-tech field to the outside world, playing an increasingly important role in promoting the commercialization, industrialization and internationalization of high-tech achievements as well as promoting economic and technological exchanges and cooperation between countries and regions.

During the CHTF session, MicroPort^® MedBot^® presented two of its heavyweight products: 3D Electronic Laparoscopic with "green channel" - DFVision^®, the first and only Chinese-developed orthopedic surgical robot with NMPA and FDA approval - Honghu, receiving great attention from people inside and outside the industry. The booth of MicroPort^® MedBot^® was designed in the contrasting colors of "red" and "blue", delivering a striking visual experience to the audience. The onsite audience and guests visited the booth, observed the product demonstration, got informed of the technical advantages, and experienced the operational performance on their own. They heaped praise on Honghu and DFVision^® amid an animated atmosphere at the booth.

The DFVision^® 3D Electronic Laparoscopic is the first Chinese-developed 3D electronic laparoscopic approved for marketing. With the application of self-developed high-resolution imaging objective and electron microscope structure, DFVision^® not only realizes full HD presentation of dual-channel images, but also significantly reduces the weight of the mirror body. The wider color gamut guided the onsite audience into a high-resolution 3D world. The three-dimensional and longitudinal surgical field provided by DFVision^® break through the limitations of traditional two-dimensional laparoscopic surgery, delivering excellent operation experience for both the surgeons in clinical practice and every audience that trials it at the event.

Featured with new-generation information technology and artificial intelligence, Honghu Orthopedic Surgical Robot was the "star" at the fair, and attracted the attention of every audience. With the core technology advantages of highly dexterous lightweight robotic arm, intelligent planning and navigation algorithms, Honghu is the first and only Chinese-developed surgical robot that has been certified by the National Medical Products Administration of the People’s Republic of China (NMPA) and the U.S. Food and Drug Administration (FDA). Honghu boasts technical advantages such as precise operation, efficient collaboration, safety protection and high compatibility. It empowers the surgeon’s “hands” (robotic arms), “eyes” (navigation), and “brain” (intelligent planning) in a digital manner, thereby effectively addressing the clinical bottlenecks of over-dependence on the surgeon’s experience, and the inability to achieve standardization and reproducibility.

Prof. Feng Wang, Director of the Department of Urology of The South China Hospital affiliated to Shenzhen University, delivered a speech titled “The Road to Domestic Substitution from the Perspective of Urological Laparoscopic Surgical Robot Development”, pointing out the great advantages of laparoscopic surgical robot compared to the traditional surgery from the development journey of endoscopic surgery. He said, “The breakthroughs continuously made in core surgical robot technologies and the support policies issued by the government will provide great help for independently-developed domestic surgical robot to break the monopoly of foreign products, allow more patients to benefit from surgical robot technologies, and increase the ratio of robot-assisted surgery relative to that of developed countries.”

Professor Shijian Yi, Vice President of The South China Hospital affiliated to Shenzhen University delivered an online speech titled “Experience and Thoughts on Thyroid Surgery Performed by the Domestic Surgical Robot”. He said, “The surgical robot has unique advantages in performing thyroid surgery. In order to eliminate the restrictions and obtain autonomy, large domestic medical center has developed minimally invasive surgical robots with full intellectual property with joint efforts from medical institute, universities, research and engineering. With the development and application of domestic high-end surgical robot system, the technology of performing thyroid surgery with surgical robot will be accessible to more primary hospitals, and bring more superior surgical services to the patients.”

Mr. Yu Liu, Executive Vice President and Chief Commercial Officer of MicroPort^® MedBot^®, said, “As technology and society advance, medical robotic surgeries have become a mainstream trend. The increasing demand of patients for robotic surgeries and the government’s support for domestic surgical robots have enabled robotic minimally invasive surgeries in China to grow rapidly. Looking ahead, MicroPort^® MedBot^® will continue to stay true to its original aspiration to ‘Make Surgery Easier, Safer and Less Invasive’, allow more of its leading medical technologies and products to reach more prefecture- and county-level hospitals through the High-tech Fair, and offer more learning and experience opportunities to clinicians, thus creating more intelligent surgical solutions for clinical diagnosis and treatment while delivering constant benefits to patients.

The registered trademark of Honghu is named “SkyWalker” in abroad , which is in the process of application in USA, completed registration in EU and other countries and regions.